NasdaqGS - Nasdaq Real Time Price • USD
AnaptysBio, Inc. (ANAB)
At close: May 31 at 4:00 PM EDT
Pre-Market: 8:00 AM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
22,962.00
17,157.00
10,287.00
63,175.00
75,000.00
Operating Expense
177,834.00
174,229.00
125,441.00
119,989.00
98,879.00
Operating Income
-154,872.00
-157,072.00
-115,154.00
-56,814.00
-23,879.00
Net Non Operating Interest Income Expense
-1,093.00
790.00
-13,558.00
-1,019.00
3,959.00
Other Income Expense
-7,339.00
-7,341.00
12.00
37.00
-11.00
Pretax Income
-163,304.00
-163,623.00
-128,700.00
-57,796.00
-19,931.00
Tax Provision
--
-4.00
24.00
--
--
Net Income Common Stockholders
-163,300.00
-163,619.00
-128,724.00
-57,796.00
-19,931.00
Diluted NI Available to Com Stockholders
-163,300.00
-163,619.00
-128,724.00
-57,796.00
-19,931.00
Basic EPS
-6.14
-6.08
-4.57
-2.11
-0.73
Diluted EPS
-6.14
-6.08
-4.57
-2.11
-0.73
Basic Average Shares
26,636.00
26,924.00
28,165.00
27,431.00
27,302.00
Diluted Average Shares
26,636.00
26,924.00
28,165.00
27,431.00
27,302.00
Total Operating Income as Reported
-162,211.00
-164,411.00
-115,154.00
-56,814.00
-23,879.00
Total Expenses
177,834.00
174,229.00
125,441.00
119,989.00
98,879.00
Net Income from Continuing & Discontinued Operation
-163,300.00
-163,619.00
-128,724.00
-57,796.00
-19,931.00
Normalized Income
-155,961.00
-156,280.18
-128,724.00
-57,796.00
-19,931.00
Interest Income
18,971.00
18,873.00
7,550.00
431.00
3,959.00
Interest Expense
20,064.00
18,083.00
21,108.00
1,450.00
--
Net Interest Income
-1,093.00
790.00
-13,558.00
-1,019.00
3,959.00
EBIT
-143,240.00
-145,540.00
-107,592.00
-56,346.00
-19,931.00
EBITDA
-140,852.00
-143,164.00
-105,257.00
-54,256.00
-18,314.00
Reconciled Depreciation
2,388.00
2,376.00
2,335.00
2,090.00
1,617.00
Net Income from Continuing Operation Net Minority Interest
-163,300.00
-163,619.00
-128,724.00
-57,796.00
-19,931.00
Total Unusual Items Excluding Goodwill
-7,339.00
-7,339.00
--
--
--
Total Unusual Items
-7,339.00
-7,339.00
--
--
--
Normalized EBITDA
-133,513.00
-135,825.00
-105,257.00
-54,256.00
-18,314.00
Tax Rate for Calcs
--
0.00
0.00
--
--
Tax Effect of Unusual Items
--
-0.18
--
--
--
12/31/2020 - 1/26/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TNGX Tango Therapeutics, Inc.
6.92
+3.90%
FDMT 4D Molecular Therapeutics, Inc.
24.00
-2.60%
EWTX Edgewise Therapeutics, Inc.
17.13
-2.11%
ELYM Eliem Therapeutics, Inc.
7.71
+0.65%
XNCR Xencor, Inc.
23.76
-0.54%
FENC Fennec Pharmaceuticals Inc.
6.78
-1.02%
APGE Apogee Therapeutics, Inc.
45.64
-1.55%
AVTE Aerovate Therapeutics, Inc.
17.45
-1.19%
CDT Conduit Pharmaceuticals Inc.
3.0400
+1.33%
TYRA Tyra Biosciences, Inc.
16.22
+2.98%